APUS vs ECL
Apimeds Pharmaceuticals US, Inc. (APUS) versus Ecolab Inc (ECL) — a side-by-side from cached financials, not a winner call.
Apimeds Pharmaceuticals US, Inc. (APUS) is a drug manufacturers - specialty & generic company listed on US.
Ecolab Inc (ECL) is a specialty chemicals company listed on US.
APUS does not have a complete income-statement cache yet.
Latest reported ECL revenue for 2024-12-31 was $4.01B. Net income was $2.13B. Revenue was up 0.2% from 2024-09-30 to 2024-12-31. ECL currently screens at market cap $72.05B and trailing P/E 34.6.
APUS currently screens at market cap $2.4M. ECL currently screens at market cap $72.05B and trailing P/E 34.6.
Not investment advice. Open the APUS and ECL stock pages for the full models.
Not investment advice.